SOAT1 and systemic sclerosis: The Janus kinase (JAK)/STAT pathway is an attractive therapeutic target in SSc, targeting known pathobiology.<h4>Conclusion</h4>Our systematic approach, combining evidence from different bioinformatics platforms, has identified drug opportunities for repurposing/druggable targets for SSc.